Posted by Michael Wonder on 18 Jul 2017
Cardiome announces Health Canada approval of Aggrastat high dose bolus regimen
17 July 2017 - Cardiome Pharma Corporation today announced that the Therapeutic Products Directorate of Health Canada has approved the Aggrastat (tirofiban hydrochloride) 25 mcg/kg dose bolus regimen, as requested under the Company’s supplemental new drug submission.
The 25 mcg/kg Aggrastat HDB regimen (25 mcg/kg over three minutes, followed by a maintenance infusion of 0.15 mcg/kg/min) will now become the recommended dose to reduce the rate of refractory ischaemic conditions, new myocardial infarction and death in high-risk patients with non-ST-elevation acute coronary syndrome who undergo early percutaneous coronary intervention.
